Phase I Dose Escalation Study of Tirapazamine (NSC 130181) in Combination With Carboplatin and Paclitaxel in Advanced Malignant Solid Tumors

Fecha de inicio: 1 de marzo de 2000

DISEASE CHARACTERISTICS: Histologically or cytologically confirmed advanced or metastatic malignant solid tumor not curable by resection or other standard therapy No symptomatic brain metastases Brain metastases allowed provided controlled with surgical excision and/or radiotherapy PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: At least 3 months Hematopoietic: WBC at least 3,000/mm3 Absolute neutrophil count at least 1,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 1.5 mg/dL SGOT no greater than 2 times upper limit of normal Renal: Creatinine normal Creatinine clearance at least 60 mL/min Cardiovascular: No New York Heart Association class III or IV congestive heart failure Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception during and for 3 months after study No history of allergic reactions to appropriate diuretics or antiemetics administered in conjunction with protocol chemotherapy (e.g., 5-HT3 antagonists) No other concurrent uncontrolled illness that would preclude study therapy No medical, social, or psychological factors that would preclude study therapy No clinically significant hearing loss PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks since prior chemotherapy (6 weeks for mitomycin and nitrosoureas) and recovered No more than 2 prior chemotherapy regimens No prior combination paclitaxel and carboplatin Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered No concurrent radiotherapy Surgery: See Disease Characteristics Recovered from prior surgery Other: At least 30 days since other prior investigational drugs No other concurrent anticancer therapy No other concurrent investigational agents